Showing results (411-420 of 437) with videos related to
Sort By:
Pageof 44
NPJ Precision Oncology|June 29, 2022
Molecular characterization of low-grade serous ovarian carcinoma identifies genomic aberrations according to hormone receptor expressionDane Cheasley, Marta Llaurado Fernandez, Martin Köbel, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 8, 2010
Somatic mutations in BRCA1 and BRCA2 could expand the number of patients that benefit from poly (ADP ribose) polymerase inhibitors in ovarian cancerBryan T J Hennessy, Kirsten M Timms, Mark S Carey, et al.The Journal of Pathology|September 9, 2020
Genomic analysis of low-grade serous ovarian carcinoma to identify key drivers and therapeutic vulnerabilitiesDane Cheasley, Abhimanyu Nigam, Magnus Zethoven, et al.International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|August 17, 2023
Low-grade serous ovarian cancer: expert consensus report on the state of the scienceRachel N Grisham, Brian M Slomovitz, Nicole Andrews, et al.The Journal of Pathology|May 15, 2026
Identifying therapeutic targets in low-grade serous ovarian carcinomas with no specific molecular profileKathleen I Pishas, Karla J Cowley, Evanny Marinovic, et al.British Journal of Cancer|October 11, 2012
Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancerV Abkevich, K M Timms, B T Hennessy, et al.Clinical Advances in Hematology & Oncology : H&O|June 19, 2012
The role of the fallopian tube in ovarian cancerAlicia A Tone, Shannon Salvador, Sarah J Finlayson, et al.International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|May 6, 2011
Role of molecular agents and targeted therapy in clinical trials for women with ovarian cancerJonathan A Ledermann, Christian Marth, Mark S Carey, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 24, 2009
c-Jun-NH2-kinase-1 inhibition leads to antitumor activity in ovarian cancerPablo Vivas-Mejia, Juliana Maria Benito, Ariel Fernandez, et al.Cancer Research|January 14, 2021
Multiomics Characterization of Low-Grade Serous Ovarian Carcinoma Identifies Potential Biomarkers of MEK Inhibitor Sensitivity and Therapeutic VulnerabilityRaunak Shrestha, Marta Llaurado Fernandez, Amy Dawson, et al.Pageof 44